Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic immune tolerance for central nervous system autoimmune diseases - Prospects, challenges and pitfalls.

Seminars in immunology·2026
Same author

Distinct Clinico-pathogenic Subgroups in Pediatric Lyme Neuroborreliosis.

Open forum infectious diseases·2026
Same author

Anoctamin-2-specific T cells link Epstein-Barr virus to multiple sclerosis.

Cell·2026
Same author

EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation.

Cell·2026
Same author

Protocol for the characterization of autoproliferating B and T cells from persons with multiple sclerosis.

STAR protocols·2025
Same author

HLA Ligand Atlas DIA: extending the benign immunopeptidomics resource with increased sensitivity through data-independent acquisition mass spectrometry.

Journal for immunotherapy of cancer·2025

Related Experiment Video

Updated: Jul 5, 2026

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Getting specific: monoclonal antibodies in multiple sclerosis.

Andreas Lutterotti1, Roland Martin

  • 1Institute for Neuroimmunology and Clinical MS Research, Center for Molecular Neurobiology Hamburg, University Medical Center Eppendorf, Hamburg, Germany.

The Lancet. Neurology
|May 20, 2008
PubMed
Summary

Newer monoclonal antibody therapies show promise for multiple sclerosis (MS) treatment, overcoming earlier production and safety concerns. These advanced treatments offer improved efficacy compared to traditional immunomodulatory drugs for MS patients.

More Related Videos

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
13:14

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

Related Experiment Videos

Last Updated: Jul 5, 2026

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
11:10

Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study

Published on: June 29, 2016

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
13:14

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) treatments were limited to immunomodulatory drugs (interferon beta, glatiramer acetate) and mitoxantrone for over a decade.
  • Natalizumab, an alpha4 integrin-targeting monoclonal antibody, offers improved efficacy and safety for MS.
  • Previous challenges with monoclonal antibody therapy, including immunogenicity and production, have largely been resolved.

Purpose of the Study:

  • To review the evolving landscape of multiple sclerosis therapeutics.
  • To highlight the growing role and potential of monoclonal antibodies in MS treatment.
  • To discuss the advancements that have made monoclonal antibodies a viable and promising therapeutic option for MS.

Main Methods:

  • Review of existing literature on multiple sclerosis therapies.
  • Analysis of clinical trial data and regulatory approvals for MS treatments.
  • Examination of the development and challenges of monoclonal antibody production and application.

Main Results:

  • Monoclonal antibodies, including natalizumab, demonstrate superior efficacy in MS treatment compared to older therapies.
  • Overcoming historical challenges in monoclonal antibody development has paved the way for their successful application in MS.
  • Ongoing research is exploring novel targets and antibody-based therapies for MS.

Conclusions:

  • Monoclonal antibodies represent a significant advancement in multiple sclerosis therapy.
  • The therapeutic potential of monoclonal antibodies for MS is substantial and continues to expand.
  • Further investigation into novel targets and antibody therapies promises improved outcomes for MS patients.